In this article, we will discuss Avapritinib (Dosage Overview). So, let’s get started.
PDGFRA Exon 18 Mutation-Positive Unresectable or Metastatic Gastrointestinal
Stromal Tumor (GIST)
Avapritinib is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
Advanced Systemic Mastocytosis (AdvSM)
Avapritinib is indicated for the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).
Limitations of Use:
Avapritinib is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 X 109/L.
Patient Selection for GIST Harboring PDGFRA Exon 18 Mutations
Select patients for treatment with AYVAKIT based on the presence of a PDGFRA exon 18 mutation. An FDA-approved test for the detection of exon 18 mutations is not currently available.
Recommended Dosage for GIST Harboring PDGFRA Exon 18 Mutations
The recommended dosage of Avapritinib is 300 mg orally once daily in patients with GIST. Continue treatment until disease progression or unacceptable toxicity.
Recommended Dosage for Advanced Systemic Mastocytosis
The recommended dosage of Avapritinib is 200 mg orally once daily in patients with AdvSM. Continue treatment until disease progression or unacceptable toxicity.
Administer Avapritinib orally on an empty stomach, at least 1 hour before or 2 hours after a meal.
Do not make up for a missed dose within 8 hours of the next scheduled dose.
Do not repeat dose if vomiting occurs after Avapritinib but continue with the next scheduled dose.